Search Prime Grants

UG3DA056884

Cooperative Agreement

Overview

Grant Description
Novel antagonists as fentanyl overdose rescue therapies.
Awardee
Regents Of The University Of Michigan
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
93.279 - Drug Abuse and Addiction Research Programs
Awarding / Funding Agency
National Institute on Drug Abuse (NIDA) [HHS - NIH]
Place of Performance
Michigan United States
Geographic Scope
State-Wide
Related Opportunity
Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional) (RFA-DA-22-022)
Analysis Notes
Amendment Since initial award the total obligations have increased 99% from $735,549 to $1,464,573.
Regents Of The University Of Michigan was awarded Novel antagonists as fentanyl overdose rescue therapies Cooperative Agreement UG3DA056884 worth $1,464,573 from National Institute on Drug Abuse in August 2022 with work to be completed primarily in Michigan United States. The grant has a duration of 2 years and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional).

Status
(Complete)

Last Modified 12/17/24

Period of Performance
8/1/22
Start Date
7/31/24
End Date
100% Complete

Funding Split
$1.5M
Federal Obligation
$0.0
Non-Federal Obligation
$1.5M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG3DA056884

Transaction History

Modifications to UG3DA056884

Additional Detail

Award ID FAIN
UG3DA056884
SAI Number
UG3DA056884-1779939988
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
GNJ7BBP73WE9
Awardee CAGE
03399
Performance District
MI-90
Senators
Debbie Stabenow
Gary Peters

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $1,464,573 100%
Modified: 12/17/24